Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.

Biotechnology

Cue Biopharma

Dan Passeri

Siddhartha Shrivastava

Andrey Antov

Matteo Levisetti

Steven Quayle

Peter Sheridan

Apollina Goel

Natasha Girgis

James Murray

Colin Sandercock

Kerri-Ann Millar

Anish Suri

The Leadership Team at Cue Biopharma is responsible for setting the strategic vision and direction of the company, guiding the development of innovative immunotherapy solutions. Comprising experts in science, finance, and legal affairs, this team collaborates to ensure the effective execution of projects, oversees regulatory compliance, and drives financial growth, all while advancing the mission to enhance patient care through targeted immuno-modulation therapies.

Leadership Team

Research and Development Team

Legal and Regulatory Affairs

Advisory Team

Leadership Team

About

Team members

Other teams at Cue Biopharma

Research and Development Team

Legal and Regulatory Affairs

Advisory Team